<DOC>
	<DOCNO>NCT01137799</DOCNO>
	<brief_summary>This study patient stable schizophrenia investigate effect JNJ-39393406 Event Related Potentials ( Auditory Evoked Potential [ AEP ] P50 , AEP P300 Mismatch Negativity [ MMN ] ) single dose administration .</brief_summary>
	<brief_title>The Effect JNJ-39393406 Event Related Potentials Stable Schizophrenic Patients</brief_title>
	<detailed_description>This double-blind ( neither physician patient know name assign drug ) , placebo-controlled , randomize ( study drug assign chance ) , four-way-crossover trial ( participant may receive different intervention sequentially trial ) patient stable schizophrenia . The four-way-crossover treatment phase consist four blind treatment period separate wash period ( period allow entire administer drug eliminate body ) 6 14 day . The study duration patient approximately 12 week . Each patient enrol receive 3 ( 5 ) dose level JNJ-39393406 one dose placebo . Part A study include smoke patient schizophrenia precede part B include non-smoking patient schizophrenia . Safety evaluation include adverse event monitoring , vital sign clinical laboratory test . The study drug give single dose Day 1 treatment period kind liquid formulation 240 mL non-carbonated water 7:00 AM 10:30 AM . Before dose patient give standard breakfast . The propose dose level study ( Part A Part B ) range 10 200 mg .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Male 18 55 year age , inclusive A known history schizophrenia least 12 month refer psychiatrist DSMIV criterion Schizophrenia ( include subtypes ) Stable treatment least 3 month ( minor change acceptable upon confirmation sponsor representative ) Medically stable basis physical examination , medical history , vital sign , 12lead ECG perform screen . If abnormality , must consistent underlie illness study population Medically stable basis clinical laboratory test perform screen . If result serum chemistry panel , hematology , urinalysis outside normal reference range , subject may include investigator judge abnormalities deviation normal clinically significant appropriate reasonable population study . This determination must record subject source document initial investigator BMI 18 35 kg/m² inclusive ( BMI = weight/height² ) For pharmacogenomic component study subject must sign separate write informed consent indicate willingness participate Part 1 genetic testing ( mandatory ) , indicate either consent refusal Part 2 DNA storage . Subject participation genetic test component study ( Part 1 ) mandatory . Participation DNA storage component ( Part 2 ) voluntary refusal participate result ineligibility main part study A DSMIV axis I diagnosis schizophrenia Clinically significant abnormal value clinical chemistry , hematology urinalysis screen admission . It expect laboratory value generally within normal range laboratory , though minor deviation , consider clinical significance investigator , acceptable . Values ALT/AST &lt; 2 fold upper limit normal allow Clinically significant abnormal physical examination , vital sign 12 lead ECG screening . Minor deviation ECG , consider clinical significance investigator , acceptable QTcb &gt; 470ms A DSMIV diagnosis substance dependence within 6 month prior screen evaluation ( caffeine dependence exclusionary . Patients positive drug screen screen may include provide use lead DSMIV diagnosis substance dependence patient consent abstain illegal drug within 3 day prior Day 1 time study ) Treatmentresistant subject ( failure respond two different antipsychotic drug past ) PANSS score &gt; 70 Suicidal risk ( assessed investigator , prior attempt suicide , command hallucination / hopelessness ) Use clozapine within 3 month screen followup Use two antipsychotic drug within 3 month dose follow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>symptomatic treatment</keyword>
	<keyword>cognition</keyword>
	<keyword>cognitive deficit</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>